Sanctuary Advisors LLC Purchases Shares of 18,285 Natera, Inc. $NTRA

Sanctuary Advisors LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 18,285 shares of the medical research company’s stock, valued at approximately $4,963,000.

A number of other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Natera in the second quarter worth about $2,962,770,000. K.J. Harrison & Partners Inc purchased a new position in shares of Natera during the second quarter valued at approximately $5,117,000. Abbot Financial Management Inc. bought a new stake in shares of Natera in the 2nd quarter worth approximately $1,537,000. UBS Group AG boosted its position in shares of Natera by 19.4% in the 4th quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after purchasing an additional 71,355 shares in the last quarter. Finally, Eagle Health Investments LP purchased a new stake in shares of Natera in the 2nd quarter worth approximately $4,302,000. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Citigroup upped their price target on shares of Natera from $315.00 to $365.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Barclays reiterated an “overweight” rating and issued a $340.00 target price on shares of Natera in a research note on Friday, August 7th. Evercore reiterated an “outperform” rating and set a $300.00 price target on shares of Natera in a report on Monday, July 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research report on Friday, July 17th. Finally, Piper Sandler boosted their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $319.38.

Natera Stock Down 1.3%

NTRA opened at $327.72 on Tuesday. The firm has a 50 day moving average price of $276.45 and a 200-day moving average price of $230.09. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $333.56. The stock has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the company earned ($0.74) earnings per share. Natera’s revenue was up 37.7% on a year-over-year basis. As a group, analysts expect that Natera, Inc. will post -1.02 earnings per share for the current year.

Insider Activity at Natera

In other Natera news, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the transaction, the director directly owned 4,250 shares in the company, valued at $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,410 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80. Following the completion of the transaction, the insider directly owned 129,019 shares of the company’s stock, valued at $34,264,866.02. This represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 177,955 shares of company stock worth $40,704,193 in the last quarter. 5.05% of the stock is currently owned by insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.